Stetser v. Tap Pharmaceutical Products, Inc.

598 S.E.2d 570, 165 N.C. App. 1, 2004 N.C. App. LEXIS 1200
Court of Appeals of North Carolina·Decided July 6, 2004·No. COA03-901·Published·Cited by 65 cases

Opinion

*4 MARTIN, Chief Judge.

Defendants TAP Pharmaceutical Products, Inc. (TAP), Abbott Laboratories (Abbott), Johnson & Johnson (Johnson) and Ethicon Endo-Surgery (Ethicon) appeal from the trial court’s order certifying plaintiffs’ class action lawsuit against defendants. Defendant TAP also appeals a separate order denying its motion to amend its answer to add a crossclaim.

I. Facts

Plaintiffs Harry E. Stetser, Dale E. Nelson and Michael de Montbrun filed this action in New Hanover County on 31 December 2001. Plaintiffs allege that defendants inflated the price of the prescription drug Lupron® from 1991 to 2001, thereby defrauding patients and insurance companies in North Carolina and throughout the United States in violation of the federal Prescription Drug Marketing Act (PDMA). Lupron® is used to treat patients .with prostate cancer, endometriosis, female infertility, central precocious puberty in children and for preoperative treatment of patients with uterine fibroid-caused anemia: Lupron®, which is only available in liquid form, is administered by injection, usually in a doctor’s office or hospital setting.

A. Parties

Defendants Abbott and Takeda are the joint owners of defendant TAP. TAP manufactures Lupron®. Takeda is a Japanese corporation, with headquarters in Osaka, Japan. Takeda’s United States headquarters is located in Illinois. Abbott and TAP’s principal offices are located in Illinois as well. On 3 October 2001, defendant TAP entered a plea of guilty to federal criminal charges stemming from an alleged conspiracy to violate the PDMA by inflating the price of Lupron®. Defendant TAP agreed to repay the federal government for the overcharges to Medicare and other federal programs as a result of the PDMA violations.

Defendant Johnson is headquartered in New Jersey, while its wholly-owned subsidiaries Ethicon and Indigo both have headquarters in Ohio. Indigo markets the “LASEROPTIC Treatment System,” a procedure used to treat patients with enlarged prostate glands having a condition known as benign prostatic hyperplasia.

Individual defendants David Jett, Christopher Coleman, and Scott Hidalgo were employees of Indigo during the period at issue in this lawsuit. Defendant Eddy James Hack was the owner of Oncology *5 Solutions, also known as International Oncology Network, which was a community-based oncology network. Jett and Coleman are residents of North Carolina, while Hidalgo and Hack are residents of the state of Florida. Jett, Coleman, Hidalgo and Hack pled guilty to a criminal information charging them with conspiracy to violate the PDMA in connection with the diversion and marketing of Lupron®. ■

B. Members of Plaintiff Class

The named plaintiffs, Harry E. Stetser, Dale E. Nelson and Michael de Montbrun, are all residents of North Carolina. The remaining members of the class are:

All persons and entities in North Carolina and throughout the United States who paid any portion of the cost of Lupron® based upon, in whole or in part, the published AWP for Lupron® (and/or Zoladex® in LCA states). Excluded from the Class are Defendants, any entity in which Defendants have a controlling interest, and their legal representatives, heirs, successors, and any governmental entities.

According to plaintiffs, three types of individual patients were disadvantaged by defendants’ marketing scheme: (1) Government Assistance Patients (including individuals who relied on government assistance programs to pay, partially or in full, the cost of their medical care, including Medicare, Medicaid, and TRICARE [formerly known as CHAMPUS]); (2) Private Assistance Patients (including patients whose medical care was paid for in part or totally by private health insurance carriers); and (3) No Assistance Patients (individuals who had no insurance or government assistance to cover their medical costs). Although the federal government reached a settlement with several of the defendants, the settlement did not include reimbursement to individuals who were overcharged co-payments for Lupron® as a result of this conspiracy, nor did the settlement include reimbursement of private health insurance carriers for their alleged overpayments. Therefore, the plaintiff class includes individuals with no insurance nor government assistance, individuals who made co-payments for Lupron® while covered by government assistance programs, individuals who made co-payments while covered by private medical insurance, and private health insurance carriers.

C. Allegations

Plaintiffs allege defendants created an elaborate scheme in order to profit illegally from the sale of Lupron® throughout the United *6 States. Plaintiffs contend defendants used several methods to inflate the average wholesale price (AWP) of Lupron®. Government programs and private insurers usually set the amount of reimbursement to medical providers based upon the published AWP. The AWP also affects the amount of patients’ co-payments made when they receive prescription drugs. The AWP is listed in a pharmaceutical industry publication called the Red Book. The plaintiffs allege defendants deliberately reported a higher AWP to the Red Book, which increased reimbursement and co-payment amounts for government insurers, private insurers and patients.

Plaintiffs further contend defendants encouraged medical providers to administer Lupron® by selling the drug to them at its actual cost. Therefore, the medical providers were charging patients, private insurance companies and the government the higher AWP while paying a lower actual cost of the drug. The difference between the amount medical providers charged for Lupron® and the cost they paid to acquire the drug accrued to the medical providers. Defendants referred to this difference in internal memos as “spread”, “return to practice,” “return on investment” or “profit”.

Plaintiffs also allege defendants would provide free samples of Lupron® to medical providers and encourage them to seek reimbursement from the government programs, private insurers, or individual patients for those free samples. The misuse of these free samples by medical providers further inflated the AWP by increasing market demand for Lupron®. Also, defendants offered illegal incentives to medical providers to encourage them to use Lupron®, including promises of debt repayment, trips to resort areas, and free ■consulting services. Plaintiffs allege these actions encouraged physicians to use Lupron® and thereby increased the AWP of Lupron® even further.

The Lupron® price inflation scheme was a direct violation of the PDMA. Several of defendant TAP’s employees, as well as several physicians, were indicted for conspiracy to violate the PDMA. As noted above, defendant TAP pled guilty to the federal criminal conspiracy charges, along with individual defendants Jett, Coleman, Hidalgo and Hack.

D. Procedural History

Plaintiffs filed this lawsuit on 31 December 2001, asserting claims for unjust enrichment, fraud, civil conspiracy, concert of action/ *7

Free access — add to your briefcase to read the full text and ask questions with AI

Stetser v. Tap Pharmaceutical Products, Inc., 598 S.E.2d 570, 165 N.C. App. 1, 2004 N.C. App. LEXIS 1200 (N.C. Ct. App. 2004).

598 S.E.2d 570 (Stetser v. Tap Pharmaceutical Products, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Vincelette v. Court
2025 NCBC 38 (North Carolina Business Court, 2025)
Innovare, Ltd. v. Sciteck Diagnostics, Inc.
2023 NCBC 5 (North Carolina Business Court, 2023)
State v. Joyner
Court of Appeals of North Carolina, 2022
Izzy Air, LLC v. Triad Aviation
Court of Appeals of North Carolina, 2022
Wall v. AutoMoney
Court of Appeals of North Carolina, 2022
Hundley v. AutoMoney
Court of Appeals of North Carolina, 2022
Env't Holdings Grp., LLC v. Finch
2022 NCBC 25 (North Carolina Business Court, 2022)
Power Home Solar, LLC v. Sigora Solar, LLC
2021 NCBC 36 (North Carolina Business Court, 2021)
Warren Cty. DSS v. Garrelts
Court of Appeals of North Carolina, 2021
Cardiorentis AG v. Iqvia Ltd.
Supreme Court of North Carolina, 2020
GRACIANO V. BLUE SKY LOGISTICS LLC
M.D. North Carolina, 2019
Am. Realty Advisors v. Lexington Ins. Co.
2019 NCBC 58 (North Carolina Business Court, 2019)
SASSER v. SAFE HOME SECURITY, INC.
M.D. North Carolina, 2019
P&L Dev., LLC v. Bionpharma, Inc.
367 F. Supp. 3d 421 (M.D. North Carolina, 2019)
Cardiorentis Ag v. Iqvia Ltd.
2018 NCBC 137 (North Carolina Business Court, 2018)
Global Textile All., Inc. v. Tdi Worldwide, LLC
2018 NCBC 30 (North Carolina Business Court, 2018)